Background. Fibrinolysis contributes to coagulopathy after major trauma and surgery. We hypothesized that progressive haemodilution is responsible, at least in part, for increased fibrinolytic tendency of blood clot.
Major trauma and surgery induce various degrees of vascular injury and exsanguination. In the case of massive blood loss requiring infusion of large amounts of i.v. fluids, coagulation factors are reduced to 30% of normal levels after loss of 1 blood volume, and to 15% after loss of 2 blood volumes. 1 2 The loss of multiple procoagulant factors is considered significant when prothrombin time (PT) is prolonged over 1.5 times of normal. 3 Although the diagnostic value of PT to predict bleeding is questionable, 4 fresh-frozen plasma (FFP) is frequently transfused in view of prolonged PT and haemorrhage as per the current guidelines. 5 6 However, there is a paucity of data on the regulation of fibrinolytic pathway and the role of FFP, if any, in major haemodilution. We have previously demonstrated in vitro that clot resistance against tissue plasminogen activator (tPA)-induced fibrinolysis decreases after haemodilution. 7 8 Therefore, we speculated that fluid replacement using the crystalloid solution confers profibrinolytic effects by diluting endogenous antifibrinolytic elements such as plasminogen activator inhibitor-1 (PAI-1), a 2 -antiplasmin, thrombin-activatable fibrinolysis inhibitor (TAFI), and factor XIII (FXIII). Because FFP contains all the endogenous antifibrinolytic elements in plasma, it is plausible that clot stability against fibrinolysis would be better maintained if FFP were given early in massive traumatic haemorrhage. 9 10 Potential haemostatic mechanisms conferred by FFP have not been fully evaluated, whereas immunological and non-immunological complications of FFP transfusion have become obvious concerns. 6 11 12 We hypothesized that antifibrinolytic activity of FFP could be demonstrated by comparing whole blood (WB) haemodilution by normal saline vs FFP. In the first part of this study, levels of antifibrinolytic factors, thrombin generation, and thromboelastometric measurements of clot stability against tPA were compared after in vitro haemodilution (to about 40% and 15% of baseline values by normal saline and FFP). Similarly, in the second part of the study, increased fibrinolytic tendency of WB clot after moderate haemodilution was evaluated in patients undergoing off-pump coronary artery bypass (OPCAB) surgery in which antifibrinolytic therapy is not routinely implemented.
Methods
After institutional approval and informed written consent, blood samples were collected into 5 ml Vacutainer tubes (Beckton-Dickinson, Franklin Lakes, NJ, USA) containing sodium citrate 3.2% (0.5 ml) from six healthy volunteers (three females and three males, age between 24 and 63 yr) who had not received any drugs in the preceding 2 weeks and had no history of coagulopathy. In addition, pre-and postoperative blood samples from 10 patients undergoing OPCAB surgery involving more than three distal anastomoses were collected after informed written consent. All samples were obtained before heparin administration and after heparin reversal by protamine but before any other haemostatic intervention. OPCAB patients were chosen because dilutional effects are often present after surgery, but antifibrinolytics are not routinely used. Transfusion practice during OPCAB surgery was guided by the anaesthetist in charge and was not influenced by the study. One patient was referred to surgery with the use of cardiopulmonary bypass, and therefore was excluded, leaving nine patients for analyses (four females and five males, age between 50 and 79 yr).
During the experiments, all blood samples, diluted and undiluted, were either used immediately or centrifuged at 2000Âg for 20 min (room temperature) to obtain platelet-poor plasma (PPP) which was stored at 2808C until analysis. For the in vitro model of haemodilution, WB was diluted 1:1 and 1:3 v/v with normal saline or allogeneic type-matched FFP, and haematocrit was restored to 23-25% by adding allogeneic type-matched RBC concentrate (haematocrit 52-63%). This dilution model has been described previously 7 and led to a total dilution of coagulation factors and platelets to about 2:5 (40%) and 1:6 (15 -20%) of baseline, respectively. Fibrinogen has been shown to be protective against fibrinolysis. 7 Therefore, in WB samples diluted to 15% of baseline with saline, fibrinogen (Haemocomplettan w P; CSL Behring, Marburg, Germany) was substituted at a concentration of 2.7 g litre 21 which approximates the concentration of fibrinogen in FFP. These samples were used only for thromboelastometric measurements.
Laboratory measurements
We determined the following coagulation and antifibrinolytic markers and factors in PPP samples at baseline, and after dilution to 40% and 15% of baseline in the in vitro haemodilution model in healthy volunteers, and in preand postoperative samples from OPCAB patients: PT, international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen, antithrombin, prothrombin (factor II), plasminogen, a 2 -antiplasmin, and TAFI. Fibrinogen concentrations were determined using a modified Clauss method. Plasma prothrombin activity was determined using the one-stage clotting assay in factor II deficient plasma according to PT. Plasma AT, plasminogen, and a 2 -antiplasmin activity were determined using a chromogenic method. These clotting and activity assays were performed on the STA Compact w analyzer (Diagnostica Stago, Parsippany, NJ, USA) using manufacturer's kits and direction. TAFI antigen was determined with an ELISA kit (Asserchrom w TAFI, Diagnostica Stago). Haemoglobin, haematocrit, and platelet count were measured by Coulter A c T Series Analyzer (Coulter Corporation, Miami, FL, USA).
Thrombin generation
The calibrated automated thrombin generation system (Thrombinoscope TM , Synapse BV, Maastricht, The Netherlands) was used to estimate the amount of thrombin generation based on the hydrolysis of a fluorogenic peptide by thrombin. Lag time, peak thrombin level, and endogenous thrombin potential were calculated as previously described by Hemker and colleagues. 13 For thrombin generation experiments, we used PPP samples at baseline and after dilution to 40% and 15% with either saline or FFP in the in vitro model and pre-and postoperative PPP samples from patients undergoing OPCAB surgery. Recalcified PPP samples were run in duplicate for thrombin generation triggered by 5 pM of relipidated tissue factor.
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Thromboelastometric measurements
Thromboelastometry (ROTEM TM ; Pentapharm, Munich, Germany) measures the viscoelastic development from thrombin-mediated fibrin polymerization and platelet activation. Thromboelastometry is characterized by specific variables described earlier. 7 Using this technique, we collected the following parameters ( Fig. 1 ): (i) coagulation time (CT; in seconds), which corresponds to the reaction time until clot formation; (ii) angle (a; in degrees), which reflects the rate of fibrin polymerization; (iii) maximal clot firmness (MCF; in millimetres), which refers to the maximal amplitude of the tracing and reflects the tensile strength of thrombus; (iv) lysis onset time (LOT; in seconds) defined as the time needed for clot firmness to decrease by 15% of MCF; and (v) lysis time (LT; in seconds) defined as the time needed for clot firmness to decrease by 90% of MCF. CT, angle, and MCF were obtained in the absence of tPA, whereas LOT and LT were evaluated in the presence of tPA.
The measurements in the blood samples from the same volunteer or patient were conducted simultaneously using three ROTEM TM analysers. All measurements were repeated twice at 378C using 300 ml of diluted or undiluted WB after recalcification with 20 ml of 0.2 M CaCl 2 and activation with 10 ml of tissue factor (EXTEM w ; Pentapharm) in the absence and presence of tPA (Alteplase w ; Genentech, South San Francisco, CA, USA) at a concentration of 0.15 mg ml
21
. 7 In OPCAB patients, we additionally conducted the pre-and postoperative analyses in the presence of cytochalasin D (FIBTEM w ; Pentapharm).
Statistics
All experiments had n!6 per condition, as this number of experiments is typically required to obtain a b!0.8 and an a 0.05 for most thromboelastometric variables as demonstrated in previous in vitro investigations. 7 Data are expressed as mean (SD) or range where appropriate after testing by the Kolmogorov -Smirnov statistics for normal distribution. Data in the in vitro model of dilution were analysed using one-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test. Data in the patient model of dilution were compared by paired t-test. A P-value of ,0.05 was considered significant. All analyses were performed using SPSS w Version 16.0 (SPSS Inc., Chicago, IL, USA). Table 1 shows blood cell counts and values for PT, INR, aPTT, fibrinogen concentration, and prothrombin, antithrombin, plasminogen, a 2 -antiplasmin, and TAFI activity in the in vitro model of dilution. After dilution to 40% and 15% of baseline with saline, all clotting parameters decreased. Accordingly, PT and aPTT were prolonged to about 1.7-to 1.8-fold of baseline after dilution to 40% and to about 3-to 3.5-fold after dilution to 15%. In contrast, after dilution to 40% and 15% with FFP, all clotting parameters remained within normal range and were not Table 2 . Blood samples after OPCAB surgery were diluted to about 60% of baseline values by administration of saline (1800 -4000 ml) and albumin 5% (500 -1000 ml). Haemoglobin, platelet count, fibrinogen, and activities of prothrombin, antithrombin, and all antifibrinolytic factors were significantly decreased, whereas PT and aPTT values increased by about 1.3-to 1.4-fold relative to baseline values (all P 0.010).
Results
Laboratory measurement
Thrombin generation
In the in vitro model of dilution, lag time was 2.6 (0.5) min at baseline and did not change significantly after progressive dilution either with saline or with FFP (all P¼1.000 vs baseline). In contrast, peak thrombin generation and endogenous thrombin potential (ETP) decreased significantly in saline diluted samples from 429 (29) and 2270 (123) nM at baseline to 249 (27) nM (P,0.001 vs baseline) and 2060 (78) nM (P¼0.034 vs baseline) after dilution to 40% and to 136 (23) nM (P,0.001) and 1800 (151) nM (P,0.001) after dilution to 15% of baseline. After dilution with FFP to 40% and 15% of baseline, peak thrombin generation and ETP did not change significantly compared with baseline except that peak thrombin level was slightly reduced to 382 (22) nM after dilution to 15% (P¼0.025 vs baseline). Figure 2 shows representative thrombin generation curves from the same volunteer in the in vitro model of dilution. In plasma samples from OPCAB patients, lag time was 4.0 (1.6) min before surgery and 4.9 (2.8) min after surgery (P¼0.899). Peak thrombin generation decreased from 427 (63) to 264 (91) nM (P¼0.001), whereas ETP decreased non-significantly from 2580 (732) to 2100 (715) nM (P¼0.160).
Thromboelastometry
For the in vitro model of dilution, CT, angle, and MCF values are shown in Table 3 . CT was prolonged and angle decreased after dilution with saline, whereas these parameters were not significantly different from baseline after dilution with FFP. MCF was reduced with any dilution, but MCF values were significantly higher after dilution with FFP compared with dilution with saline (P,0.001). Addition of fibrinogen after dilution with saline improved CT, angle, and MCF (all P,0.001) and made these values similar to dilution to 15% with FFP (all P!0.915). Figure 3 shows LOT and LT as assessed by thromboelastometry. LOT and LT values after dilution with FFP were significantly longer compared with the corresponding dilution with saline (all P,0.001). Addition of fibrinogen did not significantly improve resistance against fibrinolysis (P¼1.000 vs both dilution with saline). Table 4 shows the findings in the OPCAB patients. In agreement with our in vitro dilution model, angle and MCF decreased by 8% and 13%, respectively, after surgery, whereas CT increased by about 1.4-fold. Further, LOT and LT decreased by about 45%. In the presence of cytochalasin D, we found a decrease in MCF of 33%, and decreases of LOT and LT of about 40%.
Discussion
We present the in vitro evidence that FFP administered with intention to replace acute blood loss confers better procoagulant and antifibrinolytic activity compared with treatment with saline or fibrinogen concentrate. Further, we demonstrate that haemodilution of endogenous antifibrinolytic factors is causally related to increased fibrinolytic tendency using both in vitro and in vivo models. 
Fig 2
Representative thrombin generation curve in the PPP of a healthy volunteer after in vitro dilution: thrombin generation curves cannot be differentiated to baseline after dilution with FFP to 40% and 15%, whereas peak thrombin generation decreases dilution-dependently due to reduced concentration of procoagulant clotting factor. After dilution with saline, thrombin activity is sustained longer due to reduced antithrombin activity.
Fibrinolysis and haemodilution
Coagulopathy after major trauma and surgery has multiple aetiologies including the loss (haemorrhage) and consumption of coagulation factors and platelets, haemodilution by fluid replacement, hypothermia, acidosis, and disseminated intravascular coagulation (DIC), that is, excess procoagulant and fibrinolytic activity. 14 15 Fibrinolysis is a normal physiological response necessary to dissolve excess fibrin that is formed within blood vessels, but re-bleeding may result from the premature breakdown of fibrin at the injury site.
14 Normally, several physiological mechanisms protect fibrin (clot) against fibrinolytic enzymes. Plasma concentration of a 2 -antiplasmin is relatively high (70 mg ml 21 , 1 mM), and this plasmin inhibitor is rapidly cross-linked to fibrin a chains by thrombin-activated FXIIIa. 16 Congenital a 2 -antiplasmin deficiency is thus known to cause severe bleeding tendency due to increased susceptibility to fibrinolysis. 17 Thrombin is also involved in the activation of TAFI zymogen (5 mg ml
21
, 75 nM). Activated TAFI cleaves carboxy-terminal lysine residues from the fibrin, and prevents the binding of plasminogen. 18 Although plasma concentration of PAI-1 is low (0.01 mg ml
, 200 pM), platelets release PAI-1 from their a-granules upon activation, rendering platelet-rich thrombi resistant to fibrinolysis. 19 20 Conversely, tPA can be released from the endothelium during acute stress in response to catecholamines, thrombin, vasopressin, and other humoral factors. 21 22 Thus, fibrinolytic pathway is relatively well preserved during haemodilution in conjunction with high baseline levels of plasminogen (200 mg ml 21 , 2 mM). Indeed, increased tPA-induced fibrinolysis was readily observed on thromboelastometry (Fig. 3) after WB was diluted to 40% of baseline with normal saline leading to mild thrombocytopenia (Table 1 ). In the similar dilution with FFP, clot stability against fibrinolysis was maintained until the level of dilution was increased to 15% with FFP leading to severe thrombocytopenia ( platelet count ,40Â10 9 litre
, Table 1 ). Endogenous thrombin generation did not change after dilution with FFP, but was substantially affected after dilution with saline. However, the decrease in peak thrombin was less than expected, that is, only about 60% of baseline in the dilution to 40% of baseline and about 33% after dilution to 15% of baseline. This is in contrast to grossly prolonged PT/aPTT values after only 40% dilution with saline (Table 1) . PT/aPTT prolongations described here are in close agreement with Yuan and colleagues 3 who showed that PT/aPTT exceeded 1.5-times normal when coagulation factor levels were 50% of baseline. Unlike PT/aPTT, the thrombin generation assay is influenced not only by decreased procoagulant LOT and LT were significantly lower after dilution with saline compared with the corresponding dilution with FFP (*P,0.001). LOT and LT were comparable with baseline after dilution to 40% with FFP and decrease only after further dilution. Adding fibrinogen to the sample diluted with saline to 15% did not significantly increase LOT and LT ( § P¼1.000). (8) 70 ( Table 4 Thromboelastometric parameters in patients undergoing off-pump coronary artery bypass (OPCAB) surgery. Data are mean (SD). P-values were obtained by paired t-test. Thromboelastometric data were obtained either in the absence (CT, angle, and MCF) or in the presence of tPA (LT and LOT) after stimulation with EXTEM w or FIBTEM w as specified. CT, coagulation time; MCF, maximal clotting firmness; LOT, lysis onset time; LT, lysis time factors, but also by lower antithrombin activity; 7 thus thrombin activity is sustained longer in plasma (Table 1) . In this regard, reduced a 2 -antiplasmin and TAFI levels but not thrombin generation (to activate TAFI) seem to contribute mainly to fibrinolytic tendency. In parallel with our in vitro findings, we observed that the WB clot was more prone to tPA-induced fibrinolysis after major fluid replacements during the multi-vessel OPCAB procedure (Tables 2 and 4) .
Decreased fibrinogen level, thrombocytopenia, or both could explain our present in vitro and in vivo findings since low fibrinogen and low platelet count have been shown to increase tendency to fibrinolysis. 7 8 However, increasing the fibrinogen concentration did not significantly improve resistance against fibrinolysis in the in vitro model (Fig. 3) . The interaction between fibrin(ogen) and activated platelets (via glycoprotein IIb/IIIa) seemed to confer some antifibrinolytic function because the extent of fibrinolysis was modestly increased in the presence of cytochalasin D, an inhibitor of platelet cytoskeletal reorganization (Table 4) . Taken together, restoration of endogenous antifibrinolytic factors by FFP is presumably the main mechanism for clot protection in haemodilution-induced profibrinolytic state.
Clinical management of massive haemorrhage primarily consists of fluid resuscitation with crystalloids, colloids, or both in conjunction with red blood cell transfusion to ensure oxygen delivery. 2 5 6 Therefore, we used an in vitro model which includes haemodilution along with red blood cell supplementation to simulate clinically used resuscitation schemes. 7 The transfusion of haemostatic products used to be considered secondary to aggressive fluid resuscitation; however, this approach has been questioned recently. 23 Early intervention using FFP is increasingly utilized in massive transfusion protocols. 9 10 The empirical ratio of FFP:RBC transfusion of 1:1 seems efficacious in the retrospective analysis of massively transfused trauma cases in military and civilian studies. 10 24 Survival was significantly worse with low FFP:RBC transfusion ratio (e.g. ,1:2) compared with high FFP:RBC ratio. However, it is difficult to delineate haemostatic mechanisms of FFP from clinical data which reported normalized PT/INR because this clotting time does not reflect the full extent of thrombin generation and fibrin polymerization. 25 Further, there are increasing clinical data supporting the use of fibrinogen concentrate to reduce blood loss after major surgery. 26 -28 Therefore, the choice between FFP and fibrinogen in major haemorrhage remains controversial.
Our in vitro and in vivo data provide evidence that haemodilution by crystalloids renders clot susceptible to fibrinolysis due to dilution of endogenous antifibrinolytic factors. However, fibrinolysis may not be detectable unless thromboelastometry is performed using tPA to induce fibrinolysis (Tables 3 and 4) . Fibrinogen per se can improve most thromboelastometric variables; 7 however, increased mass of fibrin is not protected against fibrinolysis unless endogenous antifibrinolytic elements are restored (Table 1) . Levrat and colleagues 29 reported a high incidence of systemic fibrinolysis in trauma patients with higher injury severity scores. Although these investigators did not provide data on fluid resuscitation, lower platelet count and coagulation factor levels suggest that high-risk patients required more crystalloids for haemodynamic stabilization, and thus incurred more haemodilution. Further, haemodilution by colloids seems to increase susceptibility to fibrinolysis even more than crystalloids. 30 Our findings related to haemodilution also provide a biochemical basis for the clinical trial (Crash-2) which investigated the effectiveness of tranexamic acid in trauma patients. 31 32 In cardiac surgery, antifibrinolytic agents are used routinely 33 because the extracorporeal circulation is presumed to induce hyperfibrinolysis via contact activation, and resultant coagulopathy. Antifibrinolytics have been shown to decrease blood product usage. 33 On the contrary, antifibrinolytic therapy is infrequently used in OPCAB surgery for fear of hypercoagulable state, and thrombotic complications. Our present data seem to support potential usefulness of antifibrinolytic agents in cases of extensive haemodilution. In agreement, several published doubleblind randomized studies showed that tranexamic acid was effective in reducing postoperative blood loss and requirements for blood-derived products in OPCAB surgery. 34 Our data also suggest that FFP supports endogenous antifibrinolytic activity if given in sufficient amounts as shown by reduced fibrinolysis on thromboelastometry. In the case of massive haemorrhage encountered in major trauma and surgery, anticoagulant (e.g. antithrombin) and antifibrinolytic factors rapidly decrease below 40% of baseline, 35 and systemic activation of thrombin and plasmin are likely to follow. 14 36 We speculate that early intervention with FFP before the occurrence of systemic fibrinolysis might mitigate haemorrhagic tendency described as early trauma-induced coagulopathy or profibrinolytic DIC. 10 36 Obviously, there are safety concerns with the routine use of FFP which limit its therapeutic benefits. 11 12 First, FFP should not be considered as a primary fluid replacement therapy, 5 6 and high volume requirement of FFP to raise factor levels can cause volume overload. Secondly, there is a potential, although low, risk of viral transmission with FFP. Such a risk may be further reduced in the future as more virus-inactivated plasma products become available. 37 The incidence of transfusion-related acute lung injury has recently decreased after the adaptation of male only donor policy for FFP. 38 However, increased risks for multi-organ failure and sepsis associated with FFP have been reported based on the retrospective analysis of transfusion data. 12 It is prudent to prospectively evaluate the potential efficacy and safety of FFP in preventing uncontrolled thrombin generation and hyperfibrinolysis in early trauma-induced coagulopathy.
Fibrinolysis and haemodilution
In conclusion, we demonstrated a haemodilutioninduced profibrinolytic state in vitro and in vivo. Although the extent of fibrinolysis occurring in individual cases is difficult to determine, blood clot is likely more susceptible to localized fibrinolysis, which can worsen bleeding related to thrombocytopenia, low fibrinogen, and other factor deficiencies after major haemorrhage. Early fluid replacement therapy using FFP might maintain appropriate levels of clotting factors, and also improve endogenous antifibrinolytic activity in the absence of exogenous antifibrinolytic therapy. Our in vitro finding on haemodilutionrelated fibrinolysis was strongly supported by the in vivo haemodilution data during OPCAB surgery. Further clinical studies are warranted to confirm our findings and to prospectively investigate the safety and efficacy of early replacement therapy using FFP vs a combination of fibrinogen concentrate and tranexamic acid.
